Metreleptin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09046 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | familial generalized lentiginosis | KG + DL |
| 2 | gastrocutaneous syndrome | KG + DL |
| 3 | Moynahan syndrome | KG + DL |
| 4 | rhabdoid tumor | KG + DL |
| 5 | osteopathia striata-pigmentary dermopathy-white forelock syndrome | KG + DL |
| 6 | acromelanosis | KG + DL |
| 7 | congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome | KG + DL |
| 8 | leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome | KG + DL |
| 9 | benign neoplasm of adrenal gland | KG + DL |
| 10 | peripheral nerve schwannoma | KG + DL |
| 11 | schwannoma of twelfth cranial nerve | KG + DL |
| 12 | sympathetic neurilemmoma | KG + DL |
| 13 | trigeminal schwannoma | KG + DL |
| 14 | microcystic/reticular schwannoma | KG + DL |
| 15 | glaucoma | KG + DL |
| 16 | lipoatrophic diabetes | KG + DL |
| 17 | Gaucher disease | KG + DL |
| 18 | proximal myopathy with extrapyramidal signs | KG + DL |
| 19 | autosomal ichthyosis syndrome with fatal disease course | KG + DL |
| 20 | pseudo-von Willebrand disease | KG + DL |
| 21 | primary release disorder of platelets | KG + DL |
| 22 | lipodystrophy due to peptidic growth factors deficiency | KG + DL |
| 23 | Cushing disease due to pituitary adenoma | KG + DL |
| 24 | familial apolipoprotein C-II deficiency | KG + DL |
| 25 | lipodystrophy-intellectual disability-deafness syndrome | KG + DL |
| 26 | progeroid syndrome, Petty type | KG + DL |
| 27 | Steel syndrome | KG + DL |
| 28 | progeria-short stature-pigmented nevi syndrome | KG + DL |
| 29 | skeletal muscle disease | KG + DL |
| 30 | neurofibromatosis | KG + DL |
| 31 | primary immunodeficiency syndrome due to p14 deficiency | KG + DL |
| 32 | inclusion myopathy | KG + DL |
| 33 | Glanzmann thrombasthenia | KG + DL |
| 34 | growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant | KG + DL |
| 35 | autosomal recessive severe congenital neutropenia due to JAGN1 deficiency | KG + DL |
| 36 | hypophosphatasia | KG + DL |
| 37 | congenital neutropenia-myelofibrosis-nephromegaly syndrome | KG + DL |
| 38 | X-linked severe congenital neutropenia | KG + DL |
| 39 | autosomal recessive severe congenital neutropenia due to CSF3R deficiency | KG + DL |
| 40 | lipase deficiency, combined | KG + DL |
| 41 | Barth syndrome | KG + DL |
| 42 | adult idiopathic neutropenia | KG + DL |
| 43 | autosomal dominant keratitis | KG + DL |
| 44 | autosomal recessive severe congenital neutropenia due to CXCR2 deficiency | KG + DL |
| 45 | X-linked lymphoproliferative disease due to SH2D1A deficiency | KG + DL |
| 46 | autosomal dominant Alport syndrome | KG + DL |
| 47 | severe neurodegenerative syndrome with lipodystrophy | KG + DL |
| 48 | Scott syndrome | KG + DL |
| 49 | autosomal dominant brachyolmia | KG + DL |
| 50 | Charcot-Marie-Tooth disease | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.